Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review
It is suggested that in patients with high baseline disease burden and aggressive tumor biology, this variant may present as a phenotype with no initial benefit and rapid progression, and repeat biopsy or circulating tumor DNA testing should be pursued as soon as safely feasible to clarify the resistance mechanism and...